UNSPSC 51383906: Flunixin meglumine

This classification denotes a nonsteroidal antiinflammatory drug C14H11F3N2O2.C7H17NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y3JK0JW3U, chemically known as 2-(.alpha.(sup 3),.alpha.(sup 3),.alpha.(sup 3)-trifluoro-2,3-xylidino)nicotinic acid compound with 1-deoxy-1-(methylamino)-d-glucitol (1:1), but more generally known as flunixin meglumine, which bears US NIH Compound Identifier 39212. Most nations, for tariff and trade purposes, schedule flunixin meglumine under HS 29333999 and SITC 51574.

As of Q4 2014, FLUNIXIN MEGLUMINE remains US FDA's Preferred Term for this commodity. Flunixin meglumine bears US NLM identifiers UMLS ID C0060503 and NCI Concept Code C76804. SMILES: CC1C(CCCC1NC2C(CCCN2)C(=O)O)C(F)(F)F.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.

UNSPSC 51383906 Flunixin meglumine is a Commodity code that describes a specific nonsteroidal anti-inflammatory veterinary pharmaceutical, but recent state and local procurement activity tagged under this code shows little substantive alignment with the code's nominal scope. The three most recent opportunities posted under or near this code — Seminole County's naloxone and drug deactivation systems procurement, Texas HHS's Request for Information on direct-to-manufacturer pharmacy programs, and Minnesota's cooperative purchasing agreement for generic multi-source pharmaceuticals and OTC products — address broad human pharmaceutical supply, pharmacy benefit management, and community health initiatives rather than the veterinary anti-inflammatory drug the code nominally describes. The mismatch between code nomenclature and actual solicitation content suggests either miscoding by the issuing jurisdictions or a structural misalignment in how this particular commodity code is being applied in state and local procurement systems.

The geographic spread of recent activity spans Florida, Texas, and Minnesota, with the Minnesota MMCAP cooperative purchasing vehicle serving multiple states including Oregon. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the county's community health building. The Texas HHS Commission issued an RFI (HHS0017013, April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription fulfillment models, while Minnesota's MMCAP posted an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products through established wholesalers. Given the code's stated focus on flunixin meglumine and the absence of recent opportunities actually procuring that product, pursuing activity under this code carries significant execution risk — vendors should verify that actual requirement matches the code designation before committing proposal resources.